ATE370249T1 - Screening einer neuen leber-syndroms und seine anwendungen - Google Patents
Screening einer neuen leber-syndroms und seine anwendungenInfo
- Publication number
- ATE370249T1 ATE370249T1 AT01960869T AT01960869T ATE370249T1 AT E370249 T1 ATE370249 T1 AT E370249T1 AT 01960869 T AT01960869 T AT 01960869T AT 01960869 T AT01960869 T AT 01960869T AT E370249 T1 ATE370249 T1 AT E370249T1
- Authority
- AT
- Austria
- Prior art keywords
- screening
- syndrome
- mdr3 gene
- mutations
- applications
- Prior art date
Links
- 208000011580 syndromic disease Diseases 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 3
- 210000004185 liver Anatomy 0.000 title 1
- 101150071913 MDR3 gene Proteins 0.000 abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 3
- 208000037011 Microlithiasis Diseases 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 230000002440 hepatic effect Effects 0.000 abstract 2
- 208000001024 intrahepatic cholestasis Diseases 0.000 abstract 2
- 230000007872 intrahepatic cholestasis Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0010428A FR2812886B1 (fr) | 2000-08-08 | 2000-08-08 | Depistage d'un nouveau syndrome hepatique et ses applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370249T1 true ATE370249T1 (de) | 2007-09-15 |
Family
ID=8853395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01960869T ATE370249T1 (de) | 2000-08-08 | 2001-08-06 | Screening einer neuen leber-syndroms und seine anwendungen |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7262011B2 (de) |
| EP (1) | EP1307593B1 (de) |
| AT (1) | ATE370249T1 (de) |
| AU (1) | AU2001282265A1 (de) |
| CA (1) | CA2417963C (de) |
| DE (1) | DE60129986T2 (de) |
| DK (1) | DK1307593T3 (de) |
| ES (1) | ES2291338T3 (de) |
| FR (1) | FR2812886B1 (de) |
| PT (1) | PT1307593E (de) |
| WO (1) | WO2002012556A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
| EP1445333A3 (de) * | 2003-02-10 | 2004-09-29 | Assistance Publique, Hopitaux De Paris | Screening eines neuen Leber-Syndroms und deren Anwendungen |
| WO2007146203A1 (en) * | 2006-06-08 | 2007-12-21 | The University Of North Carolina At Chapel Hill | Pulsing of bile compartments in sandwich-cultured hepatocytes |
| US20110038944A1 (en) * | 2009-08-13 | 2011-02-17 | Washington State University Research Foundation | Compositions and methods for diagnosis and treatment of hepatobiliary disease and associated disorders |
| ES2586931T3 (es) * | 2010-11-04 | 2016-10-19 | Albireo Ab | Inhibidores de IBAT para el tratamiento de enfermedades hepáticas |
| RU2619215C2 (ru) * | 2010-11-08 | 2017-05-12 | Альбирео Аб | Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
| WO2016167953A1 (en) * | 2015-04-16 | 2016-10-20 | Biotranex, Llc | Method of measuring inhibition of phosphatidylcholine export transport and/or formation activity |
| EP3413878B1 (de) | 2016-02-09 | 2021-04-14 | Albireo AB | Orale cholestyraminformulierungen und verwendung davon |
| EP3413877B1 (de) | 2016-02-09 | 2021-04-07 | Albireo AB | Orale cholestyraminformulierungen und verwendung davon |
| EP3413875B1 (de) | 2016-02-09 | 2020-01-29 | Albireo AB | Cholestyraminpellets und verfahren zur herstellung davon |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| JP7391048B2 (ja) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| MX2020013839A (es) | 2018-06-20 | 2021-03-25 | Albireo Ab | Formulacion farmaceutica de odevixibat. |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| CA3116098A1 (en) * | 2018-10-12 | 2020-04-16 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
| RS63899B1 (sr) | 2019-02-06 | 2023-02-28 | Albireo Ab | Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| EP4069359B1 (de) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP7665620B2 (ja) | 2019-12-04 | 2025-04-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| BR112022010505A2 (pt) | 2019-12-04 | 2022-09-06 | Albireo Ab | Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN121023009A (zh) * | 2025-10-31 | 2025-11-28 | 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) | 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521430A1 (fr) * | 1982-02-12 | 1983-08-19 | Pan Medica | Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires |
| FR2812886B1 (fr) * | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
-
2000
- 2000-08-08 FR FR0010428A patent/FR2812886B1/fr not_active Expired - Fee Related
-
2001
- 2001-08-06 AU AU2001282265A patent/AU2001282265A1/en not_active Abandoned
- 2001-08-06 WO PCT/FR2001/002553 patent/WO2002012556A1/fr not_active Ceased
- 2001-08-06 PT PT01960869T patent/PT1307593E/pt unknown
- 2001-08-06 DK DK01960869T patent/DK1307593T3/da active
- 2001-08-06 AT AT01960869T patent/ATE370249T1/de active
- 2001-08-06 ES ES01960869T patent/ES2291338T3/es not_active Expired - Lifetime
- 2001-08-06 EP EP01960869A patent/EP1307593B1/de not_active Expired - Lifetime
- 2001-08-06 DE DE60129986T patent/DE60129986T2/de not_active Expired - Lifetime
- 2001-08-06 CA CA2417963A patent/CA2417963C/fr not_active Expired - Fee Related
-
2003
- 2003-02-10 US US10/360,705 patent/US7262011B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 US US11/878,420 patent/US7888022B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 US US12/985,817 patent/US8158352B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7888022B2 (en) | 2011-02-15 |
| US20110105451A1 (en) | 2011-05-05 |
| WO2002012556A1 (fr) | 2002-02-14 |
| DK1307593T3 (da) | 2008-01-07 |
| FR2812886B1 (fr) | 2002-11-08 |
| DE60129986D1 (de) | 2007-09-27 |
| US8158352B2 (en) | 2012-04-17 |
| CA2417963A1 (fr) | 2002-02-14 |
| US7262011B2 (en) | 2007-08-28 |
| ES2291338T3 (es) | 2008-03-01 |
| AU2001282265A1 (en) | 2002-02-18 |
| FR2812886A1 (fr) | 2002-02-15 |
| US20030215843A1 (en) | 2003-11-20 |
| US20080095858A1 (en) | 2008-04-24 |
| DE60129986T2 (de) | 2008-04-30 |
| CA2417963C (fr) | 2013-04-02 |
| EP1307593B1 (de) | 2007-08-15 |
| EP1307593A1 (de) | 2003-05-07 |
| PT1307593E (pt) | 2007-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60129986D1 (de) | Screening einer neuen leber-syndroms und seine anwendungen | |
| Maldonado et al. | Aging hallmarks and the role of oxidative stress | |
| Yang et al. | The ryanodine receptor modulates the spontaneous beating rate of cardiomyocytes during development | |
| Hudgins et al. | Age-and tissue-specific expression of senescence biomarkers in mice | |
| Ryan et al. | A paternal methyl donor-rich diet altered cognitive and neural functions in offspring mice | |
| Vannucchi et al. | Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats | |
| Thomas et al. | Human angiogenin is a potent cytotoxin in the absence of ribonuclease inhibitor | |
| Birincioglu et al. | DNA base damage by the antitumor agent 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (tirapazamine) | |
| Sauve et al. | Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry | |
| Tognini et al. | Dynamic DNA methylation in the brain: a new epigenetic mark for experience-dependent plasticity | |
| J. Dabrowski et al. | Global DNA methylation patterns in human gliomas and their interplay with other epigenetic modifications | |
| Giordano et al. | Neurotoxicity of a polybrominated diphenyl ether mixture (DE-71) in mouse neurons and astrocytes is modulated by intracellular glutathione levels | |
| Hensel et al. | Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies | |
| EP0961833A4 (de) | Hyaluronidase aus menschlichem plasma | |
| AU9058091A (en) | Preparation of nucleic acid samples | |
| Park et al. | Induced short-term hearing loss due to stimulation of age-related factors by intermittent hypoxia, high-fat diet, and galactose injection | |
| Huang et al. | Extracellular vesicle-induced classical complement activation leads to retinal endothelial cell damage via MAC deposition | |
| Taylor et al. | Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus | |
| Dudek et al. | Central and peripheral stress-induced epigenetic mechanisms of resilience | |
| Smith et al. | Genetic background differences and nonassociative effects in mouse trace fear conditioning | |
| Ding et al. | The inactivation of JAK2/STAT3 signaling and desensitization of M1 mAChR in minimal hepatic encephalopathy (MHE) and the protection of naringin against MHE | |
| Okhovat et al. | Genetic variation in the developmental regulation of cortical avpr1a among prairie voles | |
| Bilkis et al. | ATP-dependent chromatin remodeler CSB couples DNA repair pathways to transcription with implications for Cockayne syndrome and cancer therapy | |
| WO2004043990A3 (en) | Human stem cell materials and methods | |
| Mari et al. | Germline mosaicism in Rett syndrome identified by prenatal diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1307593 Country of ref document: EP |